| Mr Nicholas Anthony Baird, | |
|
2000 E Lamar Blvd Ste 400, Arlington, TX 76006-7353 | |
| (817) 861-3994 | |
| Not Available |
| Full Name | Mr Nicholas Anthony Baird |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 14 Years |
| Location | 2000 E Lamar Blvd Ste 400, Arlington, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699085944 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 680522 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northstar Anesthesia Iii Pa | 0042630501 | 335 |
| Virtue Anesthesia Pllc | 1456634625 | 2 |
News Archive
Sequenom, Inc. today announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of an overabundance in maternal blood of chromosome 21, which is associated with fetal chromosome 21 aneuploidy.
The mechanism by which the brain recognizes faces has long fascinated neurobiologists, many of whom believe that the brain perceives faces as "special" and very different from other visual objects.
A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
› Verified 1 days ago
| Entity Name | Northstar Anesthesia Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912978610 PECOS PAC ID: 7315907128 Enrollment ID: O20041015000685 |
News Archive
Sequenom, Inc. today announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of an overabundance in maternal blood of chromosome 21, which is associated with fetal chromosome 21 aneuploidy.
The mechanism by which the brain recognizes faces has long fascinated neurobiologists, many of whom believe that the brain perceives faces as "special" and very different from other visual objects.
A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
› Verified 1 days ago
| Entity Name | Clearwater Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538170485 PECOS PAC ID: 1759347875 Enrollment ID: O20041209000483 |
News Archive
Sequenom, Inc. today announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of an overabundance in maternal blood of chromosome 21, which is associated with fetal chromosome 21 aneuploidy.
The mechanism by which the brain recognizes faces has long fascinated neurobiologists, many of whom believe that the brain perceives faces as "special" and very different from other visual objects.
A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
› Verified 1 days ago
| Entity Name | Virtue Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255877551 PECOS PAC ID: 1456634625 Enrollment ID: O20170214000299 |
News Archive
Sequenom, Inc. today announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of an overabundance in maternal blood of chromosome 21, which is associated with fetal chromosome 21 aneuploidy.
The mechanism by which the brain recognizes faces has long fascinated neurobiologists, many of whom believe that the brain perceives faces as "special" and very different from other visual objects.
A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
› Verified 1 days ago
| Entity Name | Northstar Anesthesia Ii Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477066405 PECOS PAC ID: 2365701737 Enrollment ID: O20180110000102 |
News Archive
Sequenom, Inc. today announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of an overabundance in maternal blood of chromosome 21, which is associated with fetal chromosome 21 aneuploidy.
The mechanism by which the brain recognizes faces has long fascinated neurobiologists, many of whom believe that the brain perceives faces as "special" and very different from other visual objects.
A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
› Verified 1 days ago
| Entity Name | Northstar Anesthesia Iii Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356968952 PECOS PAC ID: 0042630501 Enrollment ID: O20201022000080 |
News Archive
Sequenom, Inc. today announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of an overabundance in maternal blood of chromosome 21, which is associated with fetal chromosome 21 aneuploidy.
The mechanism by which the brain recognizes faces has long fascinated neurobiologists, many of whom believe that the brain perceives faces as "special" and very different from other visual objects.
A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Nicholas Anthony Baird, 2000 E Lamar Blvd Ste 400, Arlington, TX 76006-7353 Ph: () - | Mr Nicholas Anthony Baird, 2000 E Lamar Blvd Ste 400, Arlington, TX 76006-7353 Ph: (817) 861-3994 |
News Archive
Sequenom, Inc. today announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of an overabundance in maternal blood of chromosome 21, which is associated with fetal chromosome 21 aneuploidy.
The mechanism by which the brain recognizes faces has long fascinated neurobiologists, many of whom believe that the brain perceives faces as "special" and very different from other visual objects.
A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
› Verified 1 days ago
Susan R. Spence, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2000 E Lamar Blvd, Suite 400, Arlington, TX 76006 Phone: 682-227-6834 Fax: 682-227-6864 | |
Miss Meredith Tate Richardson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2000 E Lamar Blvd Ste 400, Arlington, TX 76006 Phone: 901-378-2280 | |
Gerald Nyaayo, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 707 Highlander Blvd, Arlington, TX 76015 Phone: 817-583-7100 | |
Mrs. Erin Annette Baird, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2000 E Lamar Blvd, Arlington, TX 76006 Phone: 817-861-3994 | |
Lori A. Chancellor, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2000 E Lamar Blvd, Ste 400, Arlington, TX 76006 Phone: 817-861-3994 Fax: 682-227-6869 | |
Mr. Brannon Leinart, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2000 E Lamar Blvd, Suite 400, Arlington, TX 76006 Phone: 817-861-3994 | |
Kelly Lee Thompson, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 5731 Champion Ct, Arlington, TX 76017 Phone: 619-961-6753 |